Effect of Renal Denervation on Atrial Fibrillation (ERDAF)
Arterial Hypertension, Atrial Fibrillation
About this trial
This is an interventional treatment trial for Arterial Hypertension focused on measuring arterial hypertension, atrial fibrillation, renal denervation, autonomous nervous system, implantable loop recorder, continuous monitoring, burden, insertable cardiac monitor, resistant hypertension
Eligibility Criteria
Inclusion Criteria:
Patients >18 years with resistant hypertension [Systolic Blood Pressure (SBP) ≥ 140 mmHg and/or Diastolic Blood Pressure (DBP) ≥ 90 mmHg despite treatment with ≥ 3 antihypertensive drugs of various classes, including a diuretic) and symptomatic paroxysmal or persistent AF will be included in the study after sinus rhythm restoration
Exclusion Criteria:
- Patients with permanent AF or patients with long-standing persistent AF as defined by the current ESC guidelines for the management of AF1.
- Patients with a glomerular filtration rate (eGFR)] <45 ml / min / 1.73 m2 calculated using the CKD-EPI43.
- Patients with secondary arterial hypertension.
- Patients with an established diagnosis of resistant hypertension <6 months.
- Patients with severe renal artery stenosis or previous renal artery angioplasty.
- Patients who have undergone or are about to undergo pulmonary vein isolation.
- Patients with left end-diastolic ventricle diameter >60 mm in men or >55mm in women.
- Patients with a left ventricular ejection fraction <35% in the transthoracic echocardiogram (TTE).
- Patients with AF possible reversible causes (pulmonary embolism, acute coronary syndromes, thyrotoxicosis, alcohol abuse, etc.)
- Patients with heart failure in NYHA III-IV stage.
- Patients with life expectancy <1 year.
- Pregnant women.
- Patients who are unable to give consent to participate in the study.
- Patients who do not wish to give written consent to participate in the study.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Sympathetic Renal Denervation
Conventional treatment with drug therapy
Sympathetic Renal Denervation
Conventional drug therapy of resistant hypertension